|Bid||5,120.00 x 6100|
|Ask||5,200.00 x 13000|
|Day's Range||5,117.00 - 5,205.33|
|52 Week Range||3,680.00 - 5,505.00|
|PE Ratio (TTM)||19.25|
|Dividend & Yield||2.80 (4.20%)|
|1y Target Est||N/A|
Novo Nordisk stock popped Tuesday after AstraZeneca said its Type 2 diabetes drug didn't reduce the risk of cardiovascular events in a trial.
New Research Reports for Oracle, Chubb, AstraZeneca & Others
AstraZeneca plc (AZN) announced that it has signed an agreement with Recordati S.p.A, granting commercial rights to Seloken/Seloken ZOK and associated Logimax fixed-dose combination to the latter in European markets.